[{"Assets_0_FY_USD":1174100000.0,"CommonStockSharesOutstanding_0_FY_shares":70600000.0,"NetCashProvidedByUsedInOperatingActivities_4_FY_USD":115900000.0,"NetIncomeLoss_4_FY_USD":131100000.0,"NetIncomeLoss_1_FY_USD":13100000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_4_FY_shares":72000000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_FY_shares":72900000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_FY_shares":70100000.0,"WeightedAverageNumberOfSharesOutstandingBasic_4_FY_shares":69400000.0,"StockholdersEquity_0_FY_USD":964900000.0,"EarningsPerShareBasic_1_FY_USD":0.19,"EarningsPerShareBasic_4_FY_USD":1.89,"EarningsPerShareDiluted_4_FY_USD":1.82,"EarningsPerShareDiluted_1_FY_USD":0.18,"RevenueFromContractWithCustomerExcludingAssessedTax_1_FY_USD":200900000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_4_FY_USD":772600000.0,"Ticker":"MYGN","CIK":"899923","name":"MYRIAD GENETICS INC","OfficialName":"Myriad Genetics Inc. Common Stock","form":"10-K","period":"20180630","fy":"2018.0","fp":"FY","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"1850258412.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: In Vitro & In Vivo Diagnostic Substances","Market":"NASDAQ","SP500":"nan","filed":"20180824"}]